Clinical Trial

SG2918 For Advanced Malignant Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-12-04; most recent amendment 2026-03-05.
Status change: Recruiting → Active, Not Recruiting 2026-03-05
Trial Details
NCT Number NCT06167486
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Advanced Malignant Tumors
Enrollment 17 participants
Start Date 2023-12-26
Primary Completion 2025-11-11 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-11